ES8506758A1 - Un procedimiento para preparar un compuesto de oclusion de 2-nitroximetil-6-cloropiridina - Google Patents

Un procedimiento para preparar un compuesto de oclusion de 2-nitroximetil-6-cloropiridina

Info

Publication number
ES8506758A1
ES8506758A1 ES536654A ES536654A ES8506758A1 ES 8506758 A1 ES8506758 A1 ES 8506758A1 ES 536654 A ES536654 A ES 536654A ES 536654 A ES536654 A ES 536654A ES 8506758 A1 ES8506758 A1 ES 8506758A1
Authority
ES
Spain
Prior art keywords
beta
preparation
compound
occlusion
occulusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES536654A
Other languages
English (en)
Spanish (es)
Other versions
ES536654A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of ES536654A0 publication Critical patent/ES536654A0/es
Publication of ES8506758A1 publication Critical patent/ES8506758A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Zoology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
ES536654A 1983-10-11 1984-10-10 Un procedimiento para preparar un compuesto de oclusion de 2-nitroximetil-6-cloropiridina Expired ES8506758A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58190345A JPS6081166A (ja) 1983-10-11 1983-10-11 2−ニトロオキシメチル−6−クロロピリジンのβ−シクロデキストリン包接化合物およびその製造法

Publications (2)

Publication Number Publication Date
ES536654A0 ES536654A0 (es) 1985-08-01
ES8506758A1 true ES8506758A1 (es) 1985-08-01

Family

ID=16256648

Family Applications (1)

Application Number Title Priority Date Filing Date
ES536654A Expired ES8506758A1 (es) 1983-10-11 1984-10-10 Un procedimiento para preparar un compuesto de oclusion de 2-nitroximetil-6-cloropiridina

Country Status (18)

Country Link
US (1) US4575548A (OSRAM)
EP (1) EP0141300A3 (OSRAM)
JP (1) JPS6081166A (OSRAM)
KR (1) KR850003414A (OSRAM)
CN (1) CN85102133A (OSRAM)
AU (1) AU576521B2 (OSRAM)
CA (1) CA1248523A (OSRAM)
DK (1) DK461184A (OSRAM)
ES (1) ES8506758A1 (OSRAM)
FI (1) FI843944A7 (OSRAM)
GR (1) GR80531B (OSRAM)
HU (1) HU194285B (OSRAM)
IL (1) IL73076A (OSRAM)
NO (1) NO843773L (OSRAM)
OA (1) OA07832A (OSRAM)
PH (1) PH20203A (OSRAM)
PT (1) PT79320B (OSRAM)
ZA (1) ZA847350B (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6034156A (ja) * 1983-08-08 1985-02-21 Hayashibara Biochem Lab Inc エイコサペンタエン酸包接化合物及びこれを含有した飲食物
JPS60202115A (ja) * 1984-03-27 1985-10-12 Ichiro Shibauchi エポキシ樹脂用硬化剤
ZA885069B (en) * 1987-07-24 1989-03-29 Fujisawa Pharmaceutical Co Sustained-release percutaneous preparations
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
CA1321192C (en) * 1988-04-20 1993-08-10 Abdul Majid Inclusion complexes of cyclodextrins by agglomeration
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US20040014695A1 (en) * 1992-06-19 2004-01-22 Supergen, Inc. Pharmaceutical formulation
US5824668A (en) * 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
EP1176792A1 (en) * 2000-07-24 2002-01-30 Alcatel Method and apparatus for providing an all digital loop with power-optimised mode
US20070009531A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
US20070010478A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
US20070010485A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010487A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010486A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US11812951B2 (en) 2008-06-17 2023-11-14 Apollo Endosurgery Us, Inc. Endoscopic needle assembly
US12108939B2 (en) 2008-06-17 2024-10-08 Boston Scientific Scimed, Inc. Endoscopic tissue grasping systems and methods
CA2692211C (en) * 2009-12-14 2011-09-13 Cellresin Technologies, Llc Maturation or ripening inhibitor release from polymer, fiber, film, sheet or packaging
DK2690951T3 (en) 2011-03-27 2015-12-07 Cellresin Tech Llc Cyclodextrin compositions, ARTICLES AND METHODS
US10182567B2 (en) 2011-03-27 2019-01-22 Cellresin Technologies, Llc Cyclodextrin compositions, articles, and methods
US9320288B2 (en) 2012-11-30 2016-04-26 Cellresin Technologies, Llc Controlled release compositions and methods of using
US9421793B2 (en) 2014-06-26 2016-08-23 Cellresin Technologies, Llc Electrostatic printing of cyclodextrin compositions
US11051800B2 (en) 2016-08-10 2021-07-06 Apollo Endosurgery Us, Inc. Endoscopic suturing system having external instrument channel

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2959580A (en) * 1956-10-17 1960-11-08 Univ Minnesota Formation of inclusion compounds
CH445129A (fr) * 1964-04-29 1967-10-15 Nestle Sa Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
HU182217B (en) * 1980-10-17 1983-12-28 Chinoin Gyogyszer Es Vegyeszet Process for producing inclusive complexes of cyclodextrines and strong inorganic oxyacids
JPS57142962A (en) * 1981-02-28 1982-09-03 Santen Pharmaceut Co Ltd Cyclodextrin clathrate compound of sulfur-containing compound
JPS6054304B2 (ja) * 1981-10-16 1985-11-29 株式会社バコム ジソピラミド包接化合物
US4425336A (en) * 1982-05-24 1984-01-10 Key Pharmaceuticals, Inc. 3,4-Dihydroxy-N-[3-(4-dihydroxyphenyl)-1-methyl-n-propyl]-beta-phenethylamine cyclodextrin complexes
DK311683A (da) * 1982-07-26 1984-01-27 Fujisawa Pharmaceutical Co Fremgangsmaade til fremstilling af pyridylalkylnitratforbindelser
JPS6025967A (ja) * 1983-07-21 1985-02-08 Eisai Co Ltd トリパミド包接化合物
DE3329517A1 (de) * 1983-08-16 1985-02-28 Hoechst Ag, 6230 Frankfurt Einschlussverbindung von n,n-dimethyl-2-chlor-5-(3-methyl-2-(phenylimino)-4-thiazolin-4-yl)phenylsulfonamid, verfahren zu ihrer herstellung sowie pharmazeutische praeparate
DE3337802A1 (de) * 1983-10-18 1985-04-25 Merck Patent Gmbh, 6100 Darmstadt Pharmazeutische zubereitung

Also Published As

Publication number Publication date
IL73076A (en) 1988-05-31
FI843944A0 (fi) 1984-10-08
EP0141300A3 (en) 1986-01-29
ES536654A0 (es) 1985-08-01
AU576521B2 (en) 1988-09-01
PT79320A (en) 1984-11-01
NO843773L (no) 1985-04-12
IL73076A0 (en) 1984-12-31
FI843944L (fi) 1985-04-12
PH20203A (en) 1986-10-20
OA07832A (fr) 1986-11-20
DK461184A (da) 1985-04-12
CA1248523A (en) 1989-01-10
HU194285B (en) 1988-01-28
JPS6245226B2 (OSRAM) 1987-09-25
FI843944A7 (fi) 1985-04-12
DK461184D0 (da) 1984-09-26
JPS6081166A (ja) 1985-05-09
PT79320B (en) 1986-09-08
US4575548A (en) 1986-03-11
EP0141300A2 (en) 1985-05-15
HUT36832A (en) 1985-10-28
CN85102133A (zh) 1987-01-17
GR80531B (en) 1985-01-09
KR850003414A (ko) 1985-06-17
ZA847350B (en) 1985-10-30
AU3339984A (en) 1985-04-18

Similar Documents

Publication Publication Date Title
AU548268B2 (en) 2-ammo-5-hydroxy-4-methylpyrimidinme derivatives
AU2128583A (en) Synthesis of oligosaccharides containing galactosamine-uronic acid patterns
NZ210427A (en) Process for purifying blood clotting factor (factor viii:c); pharmaceutical compositions
JPS5390368A (en) Preparation of cation-modified cellulose derivative
ES8406467A1 (es) "procedimiento para preparar nuevos benzo b tiofenos".
IE811513L (en) Benzisoselenazolones
ES438946A2 (es) Procedimiento de prreparacion de esteres cicloalquil alqui- licos de acidos que el esqueleto de eburnano
EP0141300A3 (en) An occulusion compound of 2-nitroxymethyl-6-chloropyridine with beta-cyclodextrin and process for preparation thereof
ES8600263A1 (es) Un compuesto.
GB1553595A (en) Pyrrolidones and process for their manufacture
ES8506757A1 (es) Procedimiento para preparar un compuesto de inclusion de tripamida y ciclodextrina
IL97855A0 (en) Bromide containing pharmaceutical compositions for treatment of psoriasis
BG96578A (bg) Метод за получаване на пречистени лизозимни димери
AU539763B2 (en) Prostacyclin
ES8705417A1 (es) Un procedimiento para preparar derivados de 1,5-benzoxatiepina
NO179838C (no) Fremgangsmåte for fremstilling av S-(-)-3-morfolino-4-(3-tert-butylamino-2-hydroksypropoksy)-1,2,5-tiadiazol-hemihydrat
DE3570660D1 (en) Imidazolyl compounds, process for their preparation and their use as drugs
ES462843A1 (es) Un procedimiento para la preparacion de compuestos imidazo (1,5-a) (1,4)diacepinicos.
ATE13676T1 (de) Delta-1,3,5-3-chlor-11-beta,16-alpha,17-alpha,2 - tetra-(hydroxy)-pregnan-20-on-16,17acetonidderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.
EP0187162A4 (en) Novel radioactive iodospiroperidol and process for its preparation.
PT78072A (en) An anthracycline compound a process for the production thereof a pharmaceutical composition containing the same and its use as a medicament
DE3275465D1 (en) Thiolactime ethers of delta-1-pyrrolidine, and their preparation
DZ1366A1 (fr) Nouveaux dérivés de la méthoxycarbonyl-2 n,n'-di-(triméthoxybenzoyle) pipérazine, ainsi que leur procédé de préparation.
ES8206476A1 (es) Procedimiento de preparacion de derivados de piperidina
IE41485L (en) Purification of protein conjugates